Skip to main content
SpringerLink
Log in

TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109: 3658–3666.

    Article  CAS  PubMed  Google Scholar 

  2. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD . Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007; 109: 431–448.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Pedersen-Bjergaard J, Christiansen DH, Desta F, Andersen MK . Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2006; 20: 1943–1949.

    Article  CAS  PubMed  Google Scholar 

  4. Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T . Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer 2005; 43: 227–238.

    Article  CAS  PubMed  Google Scholar 

  5. Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997; 89: 2311–2318.

    CAS  PubMed  Google Scholar 

  6. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE . Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302–1311.

    Article  CAS  PubMed  Google Scholar 

  7. Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE . FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007; 110: 1262–1270.

    Article  CAS  PubMed  Google Scholar 

  8. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111: 2776–2784.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was funded in part by the Leukaemia Research Fund of Great Britain and by Tenovus Scotland (T02/19). We are grateful to the clinical investigators who entered and managed patients in these clinical trials.

Author information

Authors and Affiliations

  1. Division of Pathology and Neurosciences, University of Dundee, Dundee, UK

    D Bowen & M J Groves

  2. Department of Haematology, Welsh School of Medicine, Cardiff University, Cardiff, UK

    A K Burnett & R Hills

  3. Department of Haematology, University College London, London, UK

    Y Patel, C Allen, C Green, R E Gale & D C Linch

Authors
  1. D Bowen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M J Groves
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A K Burnett
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Allen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R E Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Hills
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D C Linch
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Medical Research Council Adult Leukaemia Working Party, UK

Corresponding author

Correspondence to D Bowen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bowen, D., Groves, M., Burnett, A. et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia 23, 203–206 (2009). https://doi.org/10.1038/leu.2008.173

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.173

  • Springer Nature Limited

This article is cited by

Search

Navigation